Skip to content

OxSonics strengthens management team with appointment of Dr Marianna Lalla as Chief Medical Officer

Gene Saragnese joins OxSonics’ Board of Directors

First Patient Dosed in Ground-Breaking Clinical Investigation

OxSonics Appoints Dr Allison Jeynes as Chair of the Board

OxSonics Signs Evaluation Agreement with Large Pharma Company

Nicholas Adams Joins OxSonics as Chief Business Officer

OxSonics Raises £10.5m in Oversubscribed Series B2 Equity Financing

OxSonics Wins The Gold Award at the 2019 Tech Tour Contest Grand Final

OxSonics CEO Interview At BIO Investor Forum San Francisco

SonoTran® Particles Patent Granted in the United States and Japan

Underpins Company’s strategy to expand its pipeline of clinical combination studies

Oxford, UK – 6th June 2022 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, is pleased to announce that Dr Marianna Lalla has joined the Company as Chief Medical Officer (CMO). Marianna is a well-respected physician with significant experience in leading clinical trials.

Marianna will head the Company’s clinical development function to drive the clinical development of SonoTran® in combination with multiple anti-cancer therapies. Her appointment reflects OxSonics’ transition to a clinical-stage company, and its strategy to further expand its pipeline of clinical combination studies. In January 2021, the first patient was dosed in a first-in-human clinical investigation evaluating the Company’s proprietary SonoTran® Platform in patients with metastatic colorectal cancer (mCRC).

Marianna brings over 20 years of experience as a physician, both as a clinical investigator and clinical lead for numerous early and late-stage clinical studies for the pharmaceutical industry. She joins OxSonics from UCB, where she was the Global Clinical Development lead in Translational Medicine, responsible for the development of multiple early clinical-stage products. Marianna’s prior experience as a surgeon brings a deep knowledge and understanding of the development and use of medical devices in the clinic.

Glyn Edwards, Interim CEO, OxSonics, commented: “I’m delighted to welcome Marianna to the executive team as Chief Medical Officer. This is a transformational time for OxSonics as we look to expand the clinical use of SonoTran® in combination with different anti-cancer agents from current and future partnerships. Marianna brings a wealth of experience in designing and delivering early-phase clinical trials and insights spanning both medical devices and pharmaceutical development that will be invaluable as we continue to execute our clinical strategy.”

Dr Marianna Lalla, CMO, OxSonics, commented: “I’m excited to join OxSonics as it starts to generate data from the ongoing first-in-man clinical trial and I look forward to the forthcoming initiation of further SonoTran® combination clinical studies. There is a desperate need for new technologies to address the performance limitations of current drugs and I believe SonoTran® has the potential to overcome one of the major challenges in treating solid cancers – getting more anti-cancer therapy into the tumour tissue. Its unique mechanism of action will be of great interest to potential partners looking to increase the efficacy and therapeutic index of their candidates.”

-ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers. The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time. The SonoTran® drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com

Enquiries
OxSonics Therapeutics
Nicholas Adams, Chief Business Officer
+44 (0)7712 448578
nicholas.adams@oxsonics.com

Media Enquiries
Walbrook PR (PR advisors to OxSonics)
OxSonics@walbrookpr.com
Stephanie Cuthbert/ Phillip Marriage
+44 (0)7796 794 663

Oxford, UK – 31 Jan 2022  OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced the appointment of Gene Saragnese to the Board of Directors.

Gene Saragnese is a seasoned business strategist, technology thought leader, and medical imaging industry expert. He has held executive leadership positions as the Chief Executive Officer of Philips Imaging Systems, Vice President and Head of GE’s Molecular Imaging and CT business, and Chief Technology Officer and Vice President of Global Technology for GE Healthcare’s global business portfolio.

Allison Jeynes, Chair of OxSonics Board, said “I am delighted to welcome Gene to the board of Directors; he brings extensive strategic knowledge in medical imaging technology, and his 25+ years’ experience in leading product commercialisation and marketing activities on a global scale will be invaluable to the business as we establish ourselves as a clinical stage company and refine routes to commercialisation.”

Gene Saragnese commented “I believe that OxSonics’ technology can overcome a major challenge in treating a range of solid tumours. The SonoTran® platform has the potential to increase the efficacy of anti-cancer agents by increasing the dose and distribution in some of the toughest to treat cancers, and I look forward to working with the OxSonics team to get this product to market.”

Oxford, UK – 5th January 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, today announced that the first patient had been dosed in a first-in-human clinical investigation (ISRCTN17598292) evaluating its proprietary SonoTran® Platform.

SonoTran is being evaluated in a phase I/IIa multicentre clinical investigation in patients with metastatic colorectal cancer (mCRC) funded by the National Institute for Health Research (NIHR).

The clinical investigation includes three patient cohorts to evaluate:

  1. the safety of the SonoTran Platform;
  2. SonoTran’s ability to enhance the delivery of cetuximab and irinotecan into tumours in resectable mCRC patients; and
  3. SonoTran’s ability to enhance tumour response to standard of care first-line chemotherapy (cetuximab + FOLFIRI) in unresectable mCRC patients.

Cohorts 1, 2 and 3 will recruit patients at the Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals (OUH) NHS Foundation Trust. Cohort 2 will additionally recruit patients at the Queen Elizabeth Hospital, Birmingham (UHB) NHS Foundation Trust. The coordinating investigator of the whole trial and the OUH site principal investigator is Professor Rachel Kerr (Department of Oncology, University of Oxford).

CEO and Co-founder Dr Colin Story commented: “Striving to deliver smarter and better therapies to help patients tackle tough-to-treat cancers is at the heart of everything we do, so we’re delighted that SonoTran is now being evaluated clinically. After more than ten years of innovative research at the University of Oxford’s Institute of Biomedical Engineering, followed by a further eight years of pre-clinical development by the world-leading multi-disciplinary team at OxSonics, we now enter a new and very exciting chapter in OxSonics’ evolution.”

Chair of the board Dr Allison Jeynes commented: “Whilst this first-in-human clinical trial is ongoing, Oxsonics is also advancing plans to initiate further trials with partnered therapeutic agents. These activities combined we believe will result in a pipeline of revolutionary products to treat unmet medical needs of patients with solid tumours.”

Coordinating and principal investigator Prof. Rachel Kerr commented: “Over the last quarter of a century, I have been involved in colorectal cancer trials, advancing patient care with novel therapeutics. Our improvement in response rates and increased survival, even with the most intelligently designed drugs, has always been hampered by our inability to deliver these agents deep into the tumour. I believe that SonoTran provides a real opportunity to increase the permeation of drugs deep into tumours, allowing a greater proportion of patients to achieve potential tumour resection and cure; and increasing life expectancy for the rest. The fact that this technology is something that could be applicable across many different tumour types and a whole array of anticancer drugs really drives our excitement about this trial across the cancer community”

– ENDS-

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

About the National Institute for Health Research (NIHR)

The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:

NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.
For more information please visit: www.nihr.ac.uk.

About metastatic Colorectal Cancer (mCRC)

Colorectal cancer (CRC) represents the third most common cancer worldwide and the fourth most common cancer-related cause of death. Approximately 15-25% of patients have metastatic CRC (mCRC) at diagnosis, and nearly half of CRC patients will develop metastases at some point during the course of the disease. The most common site for CRC metastases is in the liver (more than 50% of patients with metastatic CRC; and in 60% of these patients, liver metastases are the only site of spread).

Oxford, UK – 1st April 2021 OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors.

Allison Jeynes, MD, FFPM (UK), is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Currently, she serves as Chief Executive Officer at Avillion LLP, a London-based drug development company focused on co-development and financing of late-stage pharmaceuticals where she is responsible for identifying high-potential opportunities to fund programs to approval.  Previously, she held senior clinical development roles at Wyeth, BMS, and Novartis and has secured numerous US and EU drug approvals.  Dr Jeynes also serves as a non-executive director of Agenus Inc. and Anaveon AG and is a special advisor to Abingworth LLP and senior advisor to Blackstone Group Inc.

Allison Jeynes commented: “I’m delighted to be joining as non-executive Chair of Oxsonics and believe that my prior clinical oncology experience as well as pharma and investor network will help Oxsonics deliver on its journey to bring this exciting technology to patients. I look forward to working alongside Colin, CEO and the rest of the experienced Board to help ensure the Company achieves its goals.”

“I’m delighted to welcome Allison as Chair of the Board. Allison has an enviable track record in the successful delivery of clinical programs both from within the pharmaceutical industry and more recently through her leadership at Avillion. I very much look forward to working with Allison to further strengthen and build the pipeline of clinical opportunities that OxSonics’ drug delivery platform, SonoTran®, has to offer patients,” said Colin Story, OxSonics Therapeutics Co-founder and CEO.

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

Oxford, UK – 9th December 2020  OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that it has entered into an evaluation agreement with a Large Pharma company to explore the potential use of the Company’s proprietary SonoTran® Platform with a novel anti-cancer therapeutic agent.

“We are very excited to be collaborating with this Large Pharma company, a company developing highly innovative therapies for the treatment of cancer,” said Colin Story, OxSonics Therapeutics Co-founder and CEO. “This collaboration follows our strategy of applying the SonoTran Platform across in-house and partnered programs to maximise its combination with multiple drug classes and use in multiple patient groups.”

The collaboration will focus on the combination of the Company’s SonoTran Platform with a novel undisclosed clinical-stage anti-cancer therapeutic being developed by the Large Pharma company. Financial terms of the agreement are not being disclosed.

The agreement is in line with OxSonics Therapeutics’ strategy of collaborating with pharmaceutical and biotechnology companies to significantly enhance the tumour penetration of anti-cancer therapies such as antibodies, antibody drug conjugates (ADCs), oncolytic viruses, and small molecules across a broad range of solid tumour cancer types. The SonoTran Platform can be utilised to solve a variety of unmet challenges not only related to efficacy, but also dose limiting toxicity and the enablement of optimal administration routes. Crucially, SonoTran avoids delays and development costs associated with drug reformulation making it an attractive proposition for the de-risking of clinical programs.

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

For more information please visit: www.oxsonics.com.

Nicholas Adams Joins OxSonics as Chief Business Officer

Oxford, UK – 5th August 2020  OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that Mr. Nicholas Adams has joined the company as Chief Business Officer.

Nicholas brings over 30years experience in the pharmaceutical and biotech industries and for the past 16 years has led entire Business Development functions at, and been on the Executive Teams of, Antisoma, Clavis Pharma, Redx Pharma and most recently ReNeuron. Over this time Nicholas has led or been instrumental in over 25 global deals (including in-and out-licensing, divestments, spin-outs, royalty buy-out and M&A) where the out-licensing and divestment deals generated over US$240m.

Nicholas will lead the Business Development function and drive clinician engagement for the company.

Colin Story, CEO, commented: “I’m delighted to welcome Nick to the executive team as Chief Business Officer. Nick not only brings a wealth of experience both from his earlier career in oncology clinical development but also an enviable track record of consistent high value deal making across many years in commercial roles. As we transition to a clinical stage company Nick is ideally placed to drive our partnering programmes and clinician engagement activities forward.”

Nicholas Adams, CBO, commented: “I’ve followed OxSonics impressive progress over the past 18 months and I’m delighted to join as it transitions into being a clinical stage company. I look forward to forming partnerships with Pharma companies and building a network of clinical collaborators.”

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

OxSonics® Raises £10.5m in Oversubscribed Series B2 Equity Financing

Oxford, UK – 1st July 2020  OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced that a £10.5m Series B2 financing round had been closed. The financing round consisting of existing and new investors was oversubscribed.

The capital will be used to take OxSonics’ innovative SonoTran® platform technology into first-in-human clinical trials and to fund other strategic development areas.

Colin Story, CEO, commented: “We’d like to take this opportunity to thank our existing and new investors for their participation in this financing round. In transitioning to a clinical stage company, OxSonics will see its ground-breaking SonoTran technology deployed in the oncology ward setting for those patients with ‘tough to treat’ solid tumours. The whole team at OxSonics have worked very hard to develop this world-leading technology and are equally excited to see it progress to clinical use.”

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

Oxford, UK – 10th December 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that from over 2,500 companies it has been judged the ultimate winner of the European-wide Healthtech 2019 Tech Tour Contest Final.

The 13th edition of the Tech Tour Contest Final 2019 – Europe’s leading network and investment event for high-growth technological start-ups, venture capital investors and technological corporations took place on 9-10 December 2019 in Essen, Germany.

The 125 presenting companies were invited as the ‘top-rated companies’ of the Tech Tour European Venture Contest, that took place throughout 2019 in 20 regional or sector–focused qualifying events involving over 2,500 individual companies. These top 125 were first judged by panels of investors to find a shortlist of 17 from 125 and then through a second round of “pitch battle” in front of an enlarged judging panel to find the ultimate winner in healthtech. OxSonics came top in all stages of the competition and secured 1st Place GOLD in the healthtech category.

Colin Story, CEO, commented: “This is a truly amazing result for OxSonics – to be judged the winner amongst so many healthtech companies across the whole of Europe is something to be truly proud of. This success is testament to the world leading and highly innovative technology OxSonics is developing and the first-class R&D, regulatory and commercial teams at OxSonics taking this technology forward for the benefit of patients. We are truly delighted by this achievement.”

The Tech Tour press release can be viewed here.

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

About TechTour

Founded in 1998, Tech Tour is a unique cross-border platform for growing and emerging innovative tech companies on their way to investment and funding – _from the idea to the success story. The platform supports innovative companies and their projects through online community space and in person at 25 networking events that we organise each year. Tech Tour is well known in the venture capital market with its 20-years of experience across Europe and the Middle East, and planning to enlarge our scope of work to China. For more information please visit: www.techtour.com.

Oxford, UK – 22nd October 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer presented at the 2019 BIO Investor Forum in San Francisco. Colin Story, CEO, was interviewed at the conference, and a link to the interview can be viewed here.

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

SonoTran® Particles Patent Granted in the United States and Japan

Oxford, UK – 15th October 2019 – OxSonics therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that a patent protecting its SonoTran Particles has issued in the US and is proceeding to grant in Japan.

The granted patent claims relate not only to morphological features and methods of production of the SonoTran Particles, but also to their therapeutic and diagnostic use. The patent has today been issued by the US patent office and has also been allowed, and therefore is proceeding to grant, at the Japanese patent office.

Colin Story, CEO commented: “We’re very pleased to see the SonoTran Particle patent applications proceed to grant. In conjunction with the know-how associated with their GMP manufacture, this key proprietary asset is now broadly protected. During the past 2 years patents covering the company’s ‘see as you treat’ technology have also granted across all major territories. The company now has the benefit of combined protection of consumable and hardware components of its ground-breaking platform technology.”

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.